Veterans’ RightsAn independent resource for veterans
← All decisions
Remanded (sent back)

The Board has remanded the claims for status-post BCC and right foot keratoderma due to incomplete development, including a need for new VA examinations addressing flareups of the conditions and whether topical medications are systemic therapy.

The deciding factor: The Board found that none of the previous VA examinations adequately addressed the severity of flareups or whether topical medications were systemic therapy.

Claimed conditions
status-post basal cell carcinoma (BCC), right foot keratoderma
How they argued it
Direct service connection
Exposure basis
None
Rating
Not verified here — check the original decision
Decision date
December 19, 2022
Citation
22070188

This is a plain-language summary generated by AI from a public Board of Veterans’ Appeals decision. It can contain errors — always verify against the original. Read the original VA decision (opens in a new tab) using citation 22070188.

What this means for you

A remand sends an issue back for more development, often a new examination or missing records. It does not award the benefit or decide the final outcome. The original decision explains the additional work ordered.

What you can do next

Related decisions

Other Board decisions on a similar condition or argued the same way.

Free starter guide for your own claim

Reading this because you were denied or under-rated? Get the plain-English next steps — your appeal options, the deadline that protects you, and how appeals like yours turn out. One email, no spam.

We will only use this to send the guide. No spam, unsubscribe any time. We never sell your information.

We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.

This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.